These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 38204183)
21. Highlights and hot topics in GPCR research from 'Down Under'. Smith NJ; May LT; Grimsey NL Br J Pharmacol; 2024 Jul; 181(14):2091-2094. PubMed ID: 38798136 [TBL] [Abstract][Full Text] [Related]
22. Amyloid precursor protein-mediated mitochondrial regulation and Alzheimer's disease. Lopez Sanchez MIG; van Wijngaarden P; Trounce IA Br J Pharmacol; 2019 Sep; 176(18):3464-3474. PubMed ID: 30471088 [TBL] [Abstract][Full Text] [Related]
23. Neuroimmune nexus of depression and dementia: Shared mechanisms and therapeutic targets. Herman FJ; Simkovic S; Pasinetti GM Br J Pharmacol; 2019 Sep; 176(18):3558-3584. PubMed ID: 30632147 [TBL] [Abstract][Full Text] [Related]
26. Translating the matrix. Whiteford JR; Arokiasamy S; De Rossi G Br J Pharmacol; 2019 Jan; 176(1):3-4. PubMed ID: 30525194 [TBL] [Abstract][Full Text] [Related]
27. Opioid research in the time of the opioid crisis. Traynor JR; Moron JA Br J Pharmacol; 2023 Apr; 180(7):793-796. PubMed ID: 36813266 [TBL] [Abstract][Full Text] [Related]
28. Pharmacology of cognition: a panacea for neuropsychiatric disease? Bailey SJ; Neill JC; Moran PM Br J Pharmacol; 2017 Oct; 174(19):3133-3135. PubMed ID: 28901012 [TBL] [Abstract][Full Text] [Related]
29. The proteostasis network provides targets for neurodegeneration. Newton TM; Duce JA; Bayle ED Br J Pharmacol; 2019 Sep; 176(18):3508-3514. PubMed ID: 30820936 [TBL] [Abstract][Full Text] [Related]
30. Are neuropsychiatric symptoms modifiable risk factors for cognitive decline in Alzheimer's disease and vascular dementia? Savulich G; O'Brien JT; Sahakian BJ Br J Psychiatry; 2020 Jan; 216(1):1-3. PubMed ID: 31036096 [TBL] [Abstract][Full Text] [Related]
31. Highlights into the pharmacology of nutraceuticals. Andrew R; Izzo AA Br J Pharmacol; 2020 Mar; 177(6):1209-1211. PubMed ID: 32133625 [TBL] [Abstract][Full Text] [Related]
32. New insights into the yin and yang of the endocannabinoid system in health and disease. Wainwright CL Br J Pharmacol; 2016 Apr; 173(7):1113-5. PubMed ID: 26989985 [TBL] [Abstract][Full Text] [Related]
33. Sex as a biological variable in the pathology and pharmacology of neurodegenerative and neurovascular diseases. Honarpisheh P; McCullough LD Br J Pharmacol; 2019 Nov; 176(21):4173-4192. PubMed ID: 30950038 [TBL] [Abstract][Full Text] [Related]
35. Therapeutic targeting of nuclear receptors, liver X and retinoid X receptors, for Alzheimer's disease. Fitz NF; Nam KN; Koldamova R; Lefterov I Br J Pharmacol; 2019 Sep; 176(18):3599-3610. PubMed ID: 30924124 [TBL] [Abstract][Full Text] [Related]
36. LEVELS OF PROINFLAMMATORY CYTOKINES IL-17 AND IL-23 IN PATIENTS WITH ALZHEIMER'S DISEASE, MILD COGNITIVE IMPAIRMENT AND VASCULAR DEMENTIA. Dubenko OE; Chyniak OS; Potapov OO Wiad Lek; 2021; 74(1):68-71. PubMed ID: 33851590 [TBL] [Abstract][Full Text] [Related]
37. Cannabinoids and their actions: An update. Alexander SPH; Molina-Holgado F Br J Pharmacol; 2019 May; 176(10):1359-1360. PubMed ID: 31032895 [TBL] [Abstract][Full Text] [Related]
38. Adrenoceptors-New roles for old players. Michel MC; Bond RA; Summers RJ Br J Pharmacol; 2019 Jul; 176(14):2339-2342. PubMed ID: 31240712 [TBL] [Abstract][Full Text] [Related]
39. From primordial gas to the medicine cabinet. Papapetropoulos A; Wallace JL; Wang R Br J Pharmacol; 2020 Feb; 177(4):715-719. PubMed ID: 31726475 [TBL] [Abstract][Full Text] [Related]